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Abstract
Recently, targeted drug delivery systems have gained much more interest for
delivering varieties of drugs as well as imaging agents specifically to the targeted
disease cells or tissues. These are well known for their increased precision and
accuracy in mode of drug delivery along with reduced side effects. Though numer-
ous carriers are being employed for drug targeting, the solid lipid based
nanoparticles (SLNs) are preferred over them owing to their ability to encapsulate
wide varieties of drugs, biocompatibility, ease of surface modification, scaling up
feasibility, and possibilities of both active as well as passive targeting to various
organs. Surface of these drug loaded SLNs can be modified by conjugating different
ligands to enhance their tissue/organ targeting ability and therapeutic efficacy to
much higher extent. In this chapter, we have discussed about the SLNs and their
different surface modified forms for passive as well as active targeting to different
organ such as (colon, breast, lungs, liver, kidney, brain, eyes, etc.) in combating
different diseases.
Keywords: SLNs, targeted drug delivery, imaging, colon, breast, eye, lungs, liver,
kidney, brain
1. Introduction
Drug delivery refers to the approaches or methods or technologies of adminis-
tering or transporting active pharmaceutical ingredient(s) and other xenobiotics
through different routes for achieving the desired therapeutic effect in human or
animal safely. The pharmacokinetics and pharmacodynamics issues of drugs are the
most important considerations of drug delivery which is profoundly integrated
with dosage form and route of administration. The kinetics of drug release, drug
concentration profile in the plasma, onset of action, duration of action, site of
action, and side effects of a drug deeply influenced by the DDS.
2. Conventional vs. targeted drug delivery systems
2.1 Conventional drug delivery systems
Conventional drug delivery system is also known as classical drug delivery
system or traditional drug delivery system, which sometimes unable to maintain the
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steady-state plasma concentration as desired for a specific time period and may not
be able to deliver the drugs to the specific site of organ or tissues may be because of
barriers in transportation for which it may be needed to administer with multiple
doses at a regular time interval or need to go for targeted drug delivery systems.
2.2 Targeted drug delivery systems
Targeted drug delivery system (TDDS) is popularly known as smart drug deliv-
ery system. The aim of the TDDS is to localize, target and to have a protected
interaction of a drug with the diseased cells/tissues of interest for a prolonged
period of time. TDDS helps in maintaining the requisite plasma and tissue drug
levels in the body and protects the healthy tissues from damage may be some times
caused by the drugs [1]. It offers various benefits over conventional DDS such as
localization of a drug to the desired or specific site, enhancement of therapeutic
efficacy, reduction in the dosing frequency and toxic side effects, controlled
biodistribution of drug, modulated pharmacokinetics, and improved patient com-
pliances [2]. The TDDS is a highly integrated DDS which needs the coordinated
effort from various experts such as biologist, chemist, engineers for its fabrication
and optimization.
2.3 Nanotechnology vs. drug delivery systems
Nanotechnology is defined as the technology which allows studying, controlling,
manipulating and manufacturing of structures or devices in the nanoscale. It is a
multi-disciplinary scientific field applying engineering and manufacturing princi-
ples at the molecular level. These nanosized objects/structures/devices, e.g.
“nanoparticles” exhibit unique properties and function that distinctly differ from
those seen from the items made up from the same materials. Nanomaterials possess
many unique characteristics such as mechanical, optical, magnetic, electrical, and
biochemical, which provoke them to intermingle with complex cellular functions in
an exceptional manner [3].
Since its introduction in 1959, the nanotechnology brought a great revolution in
all areas of sciences and particularly in drug formulation and drug delivery system
design. Nanomedicine is the medical application of nanotechnology, which plays an
imperative role in the medical biology, diagnosis, monitoring, prevention and
treatment of diseases. Since last few decades, owing to the rapid developments in
nanotechnology and carrier materials, a great advancement in the nanoparticulate
DDS has been noticed and they are taking the lead among all types of DDS [4].
The nanoparticulate DDS possesses numerous advantages such as higher intra-
cellular uptake (cells and tissues have a greater affinity and acceptability to the
nanoparticles as compared to micro/macro molecules), ability to penetrate into sub-
mucosal layer (nanometric size), greater suitability for administration through the
systemic circulation (nanometric size), greater feasibility/flexibility to develop into
a targeted DDS for targeting various sites/organs. Thus, the nanometric size, tai-
lored surface, and cross functionality of these nanoparticles will continue to explore
many unexplored research areas and may help in designing and developing new
biomedical applications [5].
2.4 Colloidal drug carrier and solid lipid nanoparticles
The term “colloid” is applied to the dispersed system where the dispersed phase
particles size are very fine and generally below 1 μm. Thus, the biphasic drug carrier
containing very fine dispersed phase particles (<1 μm) which sequester, transport
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and retain the active drug en route, while they deliver the drug within or in the
vicinity of a target is popularly known as colloidal drug carrier. These colloidal drug
carriers comprise nanoparticles, liposome, niosome, nanospheres, multiple emul-
sion, and nanosuspensions, etc. [6]. Colloidal carriers aid in solubilization of lipo-
philic drug, protect the sensitive drug from degradation in biological fluid, reduce
toxic side effect, improve patient compliances, prolong the duration of action and
drug targeting potentiality [7].
Though the polymeric nanoparticulate DDS have shown hugely impressive per-
formance for providing therapeutic benefits in the case of long term delivery of a
therapeutic agent, but still, the number of polymeric nanoparticulate formulations
in the market is still limited. This is because of polymeric toxicity, high cost of
polymers, and lack of feasibility for scaling up. Lipid based nanoparticulate DDSs
are proposed as an alternative to polymeric nanoparticulate DDS and gained tre-
mendous attention in the field of nanomedicine. These comprise liposomes,
niosomes, nanoemulsions, solid lipid nanoparticles (SLNs) and nanostructured lipid
carrier (NLCs), etc. [5].
SLNs are the second generation lipid nanocarriers that overcome most of the
limitations associated with conventional drug delivery system and other colloidal
lipid/polymeric nano carriers. It promises to offer numerous benefits including
biocompatibility and biodegradability, physiochemical stability, lower toxicity,
ability to incorporate both hydrophilic and lipophilic drugs, improved bioavailabil-
ity, enhanced in vitro and in vivo stability of drugs, controlled-release characteris-
tics, site specificity in drug delivery as well as feasibility in pilot scale up along with
its suitability in drug delivery through different routes of administration [4].
2.5 Solid lipid nanoparticles and drug targeting
In the emerging field of nanomedicine, SLNs is at the forefront. It is made up
from biocompatible/physiological lipids (e.g. partial glycerides, triglycerides, fatty
acids, wax, and steroids) that remain in solid form at room temperature. Numerous
techniques are being developed for the fabrication of SLNs using the biocompatible/
physiological lipid which has records of innocuous use in medicine [8]. Apart from
drugs, the essential materials for fabricating SLNs are solid lipids as matrix mate-
rials, emulsifiers, stabilizers, and water. The nanometric size and larger surface area
of SLNs is suitable to be embedded with some potential functionalized ligands,
antibodies, moieties, and other functional groups that help in drug targeting [5].
The real success of lipid nanoparticles relies on the development of dosage forms
that are able to improve the therapeutic index of the drugs by mounting their
concentration specifically at the targeted site or organs. Drugs can be incorporated
in SLNs which lead to offer a new model in drug delivery that could be applied for
drug targeting. The therapeutic payload of various categories of drugs (such as anti-
infective, anticancer drugs, anti-inflammatory, etc.), antigens, proteins, and nucle-
otides can be enhanced in specific site and organs by associating with SLNs. On
another side, SLNs face numerous challenges which include rapid clearance, serum
instability (dependent on the specific formulation) and nonspecific uptake by the
mononuclear phagocytic system (play a major role for opsonizing the foreign parti-
cles and remove SLNs from the circulation) [9]. The above mentioned limitations
can be nullified by conjugating different ligands to the surface of SLNs which could
help to increase the circulation time and targeted delivery of the drug to the specific
site. The targeting properties to a specific site can be further enhanced by selecting
surface markers [10]. Thus, in this article, we focused on SLNs and various ligand
conjugated SLNs which act as suitable carriers for targeting to different sites such as
lungs, brain, liver, breast, eyes, colon, kidney, etc.
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3. Solid lipid nanoparticles for lungs targeting
Targeted delivery of a drug to the lungs is gaining much more interest at the
present time, for the treatment of lungs cancer, tuberculosis, and other airborne
diseases where lungs are the primary site of action or site administration of
drugs [11]. In order to get maximum therapeutic benefits from lungs
delivery, a suitable DDS with appropriate physicochemical properties are
necessary and SLN along with ligand conjugated SLN are the most fitted on this
ground.
3.1 Solid lipid nanoparticles for active lungs targeting
The lungs offer a very high surface area for rapid absorption of drugs owing to
high vascularization and avoidance of the first pass effect. Sometimes, targeted
delivery of certain drugs to the lungs is very important not only for improving the
bioavailability and therapeutic activity but also for reducing the systemic side
effects [5].
To achieve a prolonged hypoglycemic effect, Liu et al. developed insulin-loaded
nebulized SLNs which were administered through intrapulmonary route. The
hypoglycemic effects, stability of SLN during nebulization, and deposition pattern
of the drug were evaluated. SLNs exhibited excellent protective effect for insulin
against degradation or leakage from nanospheres and were relatively stable during
nebulization via jet nebulizer. Nebulized insulin SLNs helped in improving the
bioavailability and showed significantly higher hypoglycemic effect as compared to
insulin phosphate buffer solution administered through pulmonary route. Thus
nebulized insulin-SLNs could be a promising DDS for the treatment of diabetes
[12]. In another study Bi et al. successfully developed freeze dried insulin-SLNs
suitable for intra-tracheal administration through a spray. High preservation of
insulin was noticed in SLNs after spray freeze drying. They had performed in vivo
studies on diabetic rat and observed a prolonged hypoglycemic effect [13].
Rifampicin (RIF) were successfully encapsulated into the SLNs that delivered
RIF specifically to the alveolar macrophage (AM) with strong antimycobacterial
efficacy (MIC reduced to 1/8 fold than that of the free drug). Generally, mycobac-
terium safely multiplies in the AM (acts as an incubator), as the mycobacterium is
resistant to the biocidal mechanism of AM. The developed SLNs were more stable
and the particle sizes were very much suitable for improving RIF’s uptake by AMs
which are particle size dependent [14]. Similarly, Rifabutin loaded SLNs signifi-
cantly improved uptake of the drug by the macrophages which were demonstrated
in an in vitro model [15].
Co-administration of RIF and isoniazid through SLN formulation significantly
reduced (60%) degradation of RIF (from 48.81 to 12.35%) from acidic gastric pH
owing to the presence of isoniazid. The developed SLNs promoted targeted delivery
of drug to the brain with enhanced bioavailability and lesser side effect that could
be helpful in the case of cerebral tuberculosis [16].
Significantly higher biodistribution of dexamethasone acetate (DXM) to the
lungs was achieved through intravenous administration of DXM loaded SLNs. The
area under curve (AUC) of DXM- SLNs was increased by 17.8-fold as compared to
DXM-solution. The maximum concentration of the DXM in the lungs was observed
at 0.5 h post DXM-SLNs injection [17].
Similarly higher biodistribution of amikacin (AMK) in the lungs was achieved
by pulmonary administration of AMK-SLNs as compared to the free drug adminis-
tered through i.v., which could be helpful in the treatment of cystic fibrosis [18].
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3.2 Ligand conjugated solid lipid nanoparticles for passive lungs targeting
Lungs targeted delivery of drugs is a challenging task due to the mucociliary
clearance. In this regard, the ligand-anchored DDS not only proves its potential in
achieving improved site-specific drug delivery, but also it reduces the chances of
drug uptake by reticulo-endothelial system (RES). It is believed to play a major role
in congenital defense and exhibit diversified biological activities such as antimicro-
bial, anticancer, immunomodulation, an exertion to control cell growth, binding,
and inhibition of numerous biologically active compounds. However, clinical suc-
cess of such approaches relies on the choice of appropriate ligand free from immu-
nogenic potential with the potential to provoke cargo internalization by the target
cell [19].
The mechanism of receptor mediated endocytosis of ligand anchored SLNs and
drug release technique has been shown in Figure 1.
3.2.1 Lactoferrin (Lf) conjugated solid lipid nanoparticles
In lung associated diseases, receptors of Lactoferrin (80-kDa iron-binding gly-
coprotein) is overexpressed in the lungs. Thus, Lf conjugated DDS may become a
promising tool for targeted delivery of drugs to lungs in lung-associated diseases
[20]. Rifampicin (RIF) loaded SLNs were successfully prepared and were coupled
with Lf via carbodiimide chemistry i.e., coupling of the Lf carboxylic group with the
stearylamine amine group present on the surface of the previously formed RIF
loaded SLNs in the presence of N-ethyl-N-(dimethylaminopropyl)-carbodiimide
(EDC). An in vivo biodistribution study revealed 3.05 time higher drug uptakes by
the lungs in case of Lf-RIF-SLNs as compared to unconjugated RIF-SLNs. It was
further confirmed from fluorescence photomicrographs that clearly showed access
of the Lf-coupled SLNs into the lung. Thus, lactoferrin is an efficient molecule that
can be used for targeting active agents directly to the lungs [21].
3.2.2 Wheat germ agglutinin (WGA) conjugated solid lipid nanoparticles
Conjugation of bioadhesive ligand molecules with SLNs helps in improving drug
absorption/bioavailability by increasing residence time in the GIT and reducing
Figure 1.
Mechanism of receptor mediated endocytosis of ligand anchored SLNs and drug release technique.
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dosing frequency. Lectins (a group of diverse proteins/glycoproteins) are the
bioadhesive ligand and have stable structure and receptor binding ability. It offers
resistance to enzymatic digestion/degradation, which helps in its in vivo survival for
a prolonged time period [22]. Wheat germ agglutinin (WGA) is an example of
nontoxic plant lectin which binds particularly to N-acetyl-D-glucosamine and sialic
acid on cell surfaces. Conjugation of WGA with SLNs could be helpful for targeted
delivery of antitubercular drugs to the lungs.
WGA conjugated SLNs loaded with rifampicin (WRSLNs) were successfully
developed for lungs specific delivery of rifampicin (RIF). The conjugation of WGA
to RIF loaded SLN was carried out by two-steps carbodiimide reaction reported by
Ertl et al. with slight modification [23]. Even after conjugation with the SLNs, the
WGA retained its bio-recognition activity and sugar-binding specificity [24]. From
the in vivo study result, the interaction of WRSLNs with porcine mucin was con-
firmed. However, non-conjugated SLNs did not show any conjugation with the
porcine mucin. The WRSLNs were stable at refrigerated temperature and also in
presence of electrolytes up to 1.0 M Na2SO4 concentration. The WRSLNs were 10
times more stable than RIF-SLN which could be owing to the steric stabilization by
lectin present on nanoparticle surface. Prepared WRSLNs had shown narrow size
distribution, controlled release of a drug, retention of biorecognition activity and
improved physical stability of drug against electrolyte induced flocculation [25].
3.2.3 Mannose conjugated solid lipid nanoparticles
Studies on tuberculosis revealed overexpression of the mannose receptors spe-
cifically on alveolar macrophages (AM) surfaces [26]. Keeping it in mind attempts
were taken to develop mannosylated SLN to deliver antitubercular drugs targeting
to alveolar macrophages which have higher affinity for mannose. Rifabutin loaded
mannosylated SLNs were successfully developed. Manosylation was done by ring
opening reactions followed by reaction of aldehyde groups of mannose in 0.1 M
sodium acetate buffer (pH 4.0) with the amino groups of lipid. This leads to
formation of Schiff’s base (–N=CH–), which may then get reduced to secondary
amine (–NH–CH2–) and remain in equilibrium with Schiff’s base at basic pH. In vivo
studies were conducted to evaluate for their cytotoxicity, targeting potential, AM
uptake, and hematological studies. It was reported that mannosylation improved
uptake (up to 6-fold) of rifabutin by the AM. Moreover, mannosylated rifabutin-
SLNs were less immunogenic and helped in sustained delivery of drug. Thus, the
mannosylated SLNs may be employed for AM targeted delivery of rifabutin for
effective management of TB [27].
Overexpression of mannose receptors in case of lungs cancer was reported by
numerous investigators. The mannosylated-distearoyl phosphatidyl-ethanolamine
SLNs loaded with paclitaxel (PTX) was developed for lungs targeted delivery of
PTX. Manosylation was done by ring opening reaction followed by reaction of an
aldehyde group of mannose with the free amine group provided by stearylamine
and DSPE in sodium acetate buffer (pH 4.0). The stability testing data indicated
that SLNs formulations stored at 4  2°C were more stable than those stored at
27  2°C. It was revealed that mannosylated SLNs deliver significantly higher
concentration of drug to the alveolar cell sites and showed improved antiproli-
ferative efficacy as compared to PTX solution and PTX-SLNs [28].
3.2.4 Folate conjugated solid lipid nanoparticles
The folate receptors (α- form) are overexpressed on the surface of lung tumor
cells. The extents of the overexpression are different in different types of lung
tumors (adenocarcinomas—72%, squamous cell carcinomas—51%, small cell
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carcinoma—25%, and lung metastases—30%) [29]. These receptors allow folate
derivatives to bind preferentially that permits intracellular incorporation of folate
derivative by endocytosis.
Folate-conjugated copolymer of polyethylene glycol (PEG) and N-[(2-hydroxy-
3-trimethylammonium) propyl] chitosan chloride (HTCC) SLNs loaded with Pacli-
taxel (PTX) were successfully developed. The conjugation of folate- conjugated
PEG and HTCC to RIF-SLN was carried out by carbodiimide mediated coupling
chemistry. Pulmonary administration of the developed F-PEG-HTCC–SLNs selec-
tively delivered the PTX to the lung’s cancer cells with improved penetrability and
prolonged lung residence. Moreover, the developed SLN significantly reduced the
in vitro half-maximum inhibitory concentration of PTX in M109-HiFR cells [30].
List of SLNs and their different ligand conjugated forms for lungs targeting have
been summarized in Table 1.
4. Solid lipid nanoparticles for brain targeting
Targeted delivery of drugs to the brain for is gaining much more interest at the
present time, not only for the treatment of brain tumor and other neurodegenera-
tive disorders but also for their diagnosis. Brain targeted delivery of drugs is the
most challenging task because of the presence of strongest physiological barrier, i.e.,
Sl.
no
SLN
(Type)
Lipids Preparation
method
Drugs Target Model Comments Ref.
01 SLN SA, PA Reverse micelle-
double emulsion
Insulin Lungs Male SD
rats
Improved hypoglycemic
effect
[12]
02 SLN SA, PA Modified lipid
film hydration
method
RIF AM SD rats Improved drug uptake
by AMs.
[14]
03 SLN SL,
GTS
Ultrasonication
with high
pressure
homogenization
DXM Lungs Mice Improved therapeutic
efficacy targeting to
lungs
[17]
04 Lf-
SLNs
SL Solvent injection
method
RIF LfR Albino
rats
Targeted delivery of RIF
to Lungs
[21]
05 WGA-
SLN
SA,
GMS
Single
emulsification
followed by
solvent
evaporation
RIF Mucin Porcine Controlled release of RIF [25]
06 Msy-
SLN
TSN Modified solvent
injection method
RFB MR J774 &
albino
rats
AM specific drug
delivery. Enhanced
therapeutic efficacy.
[27]
07 Msy-
SLN
TSN,
DSPE
Modified solvent
injection method
PTX MR A549 &
Male
albino
rat
Alveolar cell site
delivery of drug with
enhanced anti-
proliferative efficacy.
[28]
08 Ft-SLN CHO,
GS
Nano
precipitation
method
PTX FR HeLa &
M109-
HiFR
cells
Prolonged drug
residence time, reduced
MIC
[30]
Table 1.
List of SLNs and their different ligand conjugated forms for lungs cells targeting.
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blood brain barrier (BBB). It is a highly selective semipermeable membrane barrier
constituted by specialized microvascular endothelial cells, basement membrane and
glial cells (astrocytes, neurons, and pericytes). As long as the BBB remains integral,
the drugs remain ineffective in the brain. Though BBB is a major issue for it, yet it
offers scores of opportunities such as presence of numerous transport proteins and
specialized receptors [5].
Conventional approach for the treatment of brain tumor and other brain-related
disorders needs a higher dose of the drug that leads to systemic toxicity and sub-
stantial adverse effects on CNS and vital normal tissues. However, various
researchers have reported SLNs to be a suitable DDS targeting the brain as the SLNs
possess numerous unique characteristics, such as improved uptake of SLN by the
brain due to lipidic nature, bioacceptability and biodegradability nature, non-toxic,
nano sized particles suitable for prolonged circulation time in blood scale up feasi-
bility, absence of burst drug release effect [31]. Thus, SLN could be used as
potential as well as promising candidate for brain targeting.
4.1 Solid lipid nanoparticles for active brain targeting
SLNs are the most acceptable brain targeted DDS employed in brain tumor owing
to their ability to escape and/or inhibit P-glycoprotein in the blood–brain barrier [32].
Camptothecin (CMP) loaded SLN were successfully developed for the treatment of
glioma. Encapsulation of drug in phospholipids and conjugation with the peptide
enhances the permeation of drug across BBB, which leads to brain targeted delivery
of the drug. The developed SLN was stable in terms of size and charge within a year
of storage which might be due to appropriated acidic pH (inclusion of behenic acid
into the lipid core of the SLNs). DMPC (1,2-dimyristoyl-sn-glycero-3-phospho-
choline) membrane helps in efficient release of the incorporated CMP into the brain
parenchyma crossing the BBB. Against glioma, the developed SLNs showed higher
cell death or antitumor activity using the lowest maximal inhibitory concentration
(IC50) values. Biodistribution study revealed higher accumulation of CMP in the
brain in the case of SLNs as compared to other non-encapsulated drugs. However,
pharmacokinetics study revealed lower deposition of CMP in peripheral organs indi-
cating lesser toxicological effects in the vital organ. Thus, in short, the SLNs exhibited
enhanced accumulation, distribution, and retention of camptothecin in the animal
brain along with superior in vitro antitumor activity against glioma [33].
Riluzole (RLZ), a potent neuroprotective agent is useful in the treatment of
neurodegeneration including traumatic brain injury and amyotrophic lateral sclero-
sis. RLZ-SLNs were able to deliver the riluzole successfully to the brain which helps
in preventing acute cell damage induced by glutamate in neurodegenerative dis-
eases of motor neurons. Moreover, it also protects dopamine neuron in the case of
Parkinson’s disease. Stability studies on RLZ-SLNs were also carried out at pH 1.1,
5.5 and 7.4, and in human plasma which revealed the absence of riluzole degrada-
tion in all the investigated media [34].
Vinpocetine (VIN), a derivative of vincamine alkaloid, useful against chronic
cerebral vascular ischemia. VIN loaded SLN were successfully developed and
achieved the objectives of delivering the drugs to the brain. Release kinetics of the
developed SLN followed zero-order sustained release profile [35].
4.2 Ligand conjugated solid lipid nanoparticles for passive brain targeting
4.2.1 Lactoferrin conjugated solid lipid nanoparticles
Augmentation of drug uptake into the brain is a subtle mission in the treatment
of brain tumor. Lactoferrin (Lf) receptor present on the BBB in different species
8
Role of Novel Drug Delivery Vehicles in Nanobiomedicine
along with the cell surface of glioblastomas [36]. Keeping it in mind, various
researchers tried to target lactoferrin receptor through conjugation of lactoferrin
with SLNs for active targeting to brain tumor. Moreover, this conjugated system
showed higher stability, and drug payload.
Lactoferrin (Lf) conjugated SLNs loaded with docetaxel (DTX) were able to
show effective brain targeting efficiency. Carbodiimide chemistry was employed
for conjugation of Lf on SLN surface (Lf-SLN). Receptor saturation studies and
distribution studies of lipidic nanoparticles in the brain indicated brain targeting
mechanism for uptake in brain tumor cell and brain respectively. The Lf-SLNs were
more stable. It not only showed significantly higher DTX concentration in the brain
but also showed superior apoptotic activity when compared with unconjugated
SLNs and DTX. Thus it was confirmed that conjugation of Lf to SLN significantly
improved the targeting potential of the DTX for brain tumor [37].
4.2.2 Tamoxifen-Lactoferrin cross conjugated solid lipid nanoparticles
P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRAPs)
are localized on brain microvascular endothelial cells (BMEC) which pump out the
substances/drug out from the central nervous system. Tamoxifen (Tf), a selective
estrogen receptor modulator possibly reverse the capability of efflux transporters
like MRAPs in cancer cells [38]. Thus, incorporation of Tf could help in
preventing a wide range of medication from efflux loss. Lactoferrin (Lf)
receptors are overexpressed in BMEC and glioblastoma multiforme (GBM) cells.
It is reported that the Lf cause inhibition to the multiplication of malignant
GBM cells.
Tamoxifen (Tx) and lactoferrin (Lf) cross-conjugated carmustine (CRM)-
loaded SLNs were developed. For conjugation of Tx on CRM-SLN, the carbonyl
groups of the SLN were first activated with 0.1% (w/v) carbodiimide and 0.05%
(w/v) N-hydroxysuccinimide. The suspended SLNs were then crosslinked with
0.05%, 0.1%, 0.15%, or 0.2% (w/v) Tx at 150 rpm and 25°C for 3 h and centrifuged.
Further Lf conjugation was done by reacting Lf (0.02%, 0.04%, 0.06%, or 0.08%)
(w/v) with the activated CRM-SLNs and Tx-CRM-SLN. The conjugated SLNs were
more stable which could be due to inclusion of behenic acid into the lipid core.
These were efficiently penetrated through a monolayer of human BMEC and
human astrocytes and to target GBM cells. A 10-fold increase in the permeability of
BBB and improved the sustained release of CRM was achieved with the help of the
developed SLNs as compared to unconjugated CRM-SLNs. Thus, TX and Lf cross-
conjugated SLNs enhance the BBB permeability of the drug with improved anti-
proliferative action against GBM [39].
4.2.3 PEG conjugated solid lipid nanoparticles for gene delivery
Treatment of brain tumor through siRNA is preferable, as it can target specifi-
cally to one gene and is able to silence it in a post-transcriptional way. Moreover,
siRNA can target several functional proteins available at the BBB [40]. Treatment of
brain tumor through siRNA, needs a safe, stable, effective carrier which must be
able to cross the BBB. The SLNs are mostly preferred as it meets most of the criteria
which siRNA needs. Targeted delivery of gene by SLNs is a bi-stage system. Conju-
gation of angiopep to SLN surface for targeting the low-density lipoprotein
receptor-related protein-1(expressed in BBB) is the initial step. The proteolytic
cleavage of PEGylated lipopeptide, which releases PEG, glutamic acid residues and
release of siRNA for high silencing efficiency is the second stage [5].
siRNA encapsulated SLNs were successfully developed using a combination of
titrable cationic lipids. For effective gene delivery, it was PEGylated after
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incorporating MMP-cleavable lipopeptide. The in vitro study indicated that the
developed SLNs showed higher uptake and gene knockdown efficacy. SLNs also
showed low cytotoxicity which was owing to masking of intrinsic positive charge of
SLNs by PEGylated cleavable lipopeptide. In in vivo studies, angiopep functiona-
lization played a vital role as a mediator of transport across the BBB and targeting
to glioma [41].
4.2.4 Apolipoprotein E conjugated solid lipid nanoparticles
Low density lipoprotein (LDL) receptors are overexpressed on the BBB and
apolipoprotein E (AP-E), a plasmatic protein is easily recognized by these receptors.
Resveratrol (RSV), polyphenolic flavonoid promises to offer neuroprotective
effects which are helpful in neurological disorders like Alzheimer’s, Parkinson’s,
Huntington’s diseases, brain ischemia, and epilepsy. The AP-E conjugated resvera-
trol (RSV) SLNs were successfully developed. The binding of ApoE to the SLNs
surface was carried out by spontaneous interaction between the previously
biotinylated ApoE and the covalently attached avidin on the SLNs surface, resulting
Sl.
no
SLN
(Type)
Lipid
(s)
Preparation
method
Drugs Target Model Comments Ref.
01 SLN CP,
DMPC
High shear
homogenization
and
ultrasonication
techniques
CMP Brain Human
glioma &
Monocytic
cell line.
Wistar rats
Enhanced
accumulation of
CMP. Superior
in vitro antitumor
activity
[33]
02 SLN COMP,
SPC
Warm oil-in-
water
microemulsion
technique
RLZ Brain Male SD rats Higher
bioaccumulation
of RLZ in brain.
[34]
03 SLN SA,
GMS,
PRE,
GTP
High shear
homogenization
and
ultrasonication
techniques
VIN Brain — Zero-order
sustained drug
release kinetics
[35]
04 Lf-SLN GMS,
SA, SL
Emulsification
and solvent
evaporation
method
DTX Lf
Receptors
U-87 MG
cell lines &
Swiss albino
mice
Improved the
brain targeting
potential
[37]
05 Tf-Lf-
SLNs
TPM,
DSPE
Homogenization
followed by
centrifugation
CRM Tf and Lf
Receptors
U87MG,
HBMECs
Higher BBB
permeability.
Superior anti-
proliferative
action
[39]
06 SLN POPC,
DSPE,
CHO,
DM
Detergent
dialysis
technique
siRNA Angiopep bEnd.3 cell,
U87MG
cells,
Higher uptake
and gene
knockdown
efficacy
[41]
07 AP-E -
SLNs
CP High shear
homogenization
followed by
sonication
technique
RSV LDL
Receptor
hCMEC/D3
Cell line
Brain targeted
delivery of RSV
[42]
Table 2.
List of SLNs and their different ligand conjugated forms for brain cell targeting.
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in two different ApoE-functionalized SLNs: SLN-DSPE-ApoE and SLN-Palmitate-
ApoE. These conjugated SLNs were sufficiently stable and were able to prevail over
the issues of RSV like low solubility, degradation but also to help its brain targeted
delivery. Brain targeted delivery of RSV by such SLNs follows a bi-stage system.
The AP-E-RSV-SLNs mimic lipoprotein particles that are endocytosed into the BBB
endothelium via the LDL receptor and then transcytosed to the brain [42].
List of SLNs and their different ligand conjugated forms for brain cell targeting
have been summarized in Table 2.
5. Solid lipid nanoparticles for liver targeting
Though targeted delivery of a drug to the liver is a challenging task, still, it is
an interesting approach in the treatment of various liver disorders. In the treatment
of liver disorders, drugs targeting to the liver, face irresistible obstacles from
various physiological barriers and processes like uptake by the reticuloendothelial
system, mechanical entrapment by the pulmonary vascular bed, and opsonization
process [43].
Numerous approaches are being proposed to enhance bioaccumulation/
biodistribution of drugs to liver and hepatocytes. These approaches include both
active targeting as well as passive accumulations of nanoparticulate formulation due
to ligand (carbohydrate, peptide, antibodies conjugation) conjugated nanoparticles.
Recently, liver targeted deliveries of drugs by the SLNs are gaining much attention
in the treatment of various types of liver disorders. Thus, various liver targeting
strategies using SLNs are enlightened below.
5.1 Solid lipid nanoparticles for active targeting
Baicalin (BCL), a natural product obtained from Scutellaria baicalensis (Family:
Labiatae) popularly used in the treatment of Hepatitis-B and liver fibrosis. BCL
loaded SLNs were developed. The prepared SLNs were stable and were able to
enhance the therapeutic efficacy of BCL by improving its biodistribution in the
liver. In vivo biodistribution, targeting evaluation and in vitro anti-oxidant study
reveals that the developed BCL-SLNs have substantial liver targeting, improved anti
oxidative and hydroxyl radical scavenging abilities [44].
Ficus benjamina (Family: Moraceae) is rich in phenolic (chlorogenic, p-
coumaric, ferulic and syringic acids) and total flavonoid content that are effective
against chronic alcoholism induced fatal liver and cardio-renal injury. Ethanolic
extract of Ficus benjamina (FB) loaded in SLNs (FBSLNs) helped in
bioaccumulation of the phenolic and flavonoid content in the liver due to lipophilic
nature of SLNs. In vivo evaluation of FBSLNs against hepatic and cardio-renal injury
revealed its hepatoprotective activity which was further evident from various bio-
logical parameters and histopathological photomicrography. In the liver, accumula-
tion of aldehyde level was reduced that validated the detoxifying nature of FBSLN.
Moreover, restoration of aberrant cardio-renal biomarkers and histological conse-
quences revealed the cardio-renal protective potential of FBSLNs [45].
Berberine (BBR), an active constituent of Coptis chinensis (Family:
Ranunculaceae) have potential pharmacological effects on type-2 diabetes. It has
already been validated that BBR enhances glucose and lipid metabolism through the
activation of adenosine monophosphate-activated protein kinase (AMPK) and
improve insulin sensitivity. BBR loaded SLNs (BBR-SLNs) were developed to
improve the beneficial effect of BBR on hepatosteatosis. The effect of BBR-SLNs on
lipid metabolism were studied which revealed gaining of body weight and reduction
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in liver weight with simultaneous reduction of serum alanine transaminase and liver
triglyceride level. Biodistribution study reported 20-fold increase in the concentra-
tion of drug in the liver than that of blood. Moreover, it reduced the accumulation
of fat and lipid droplet size. It was also noticed that the expression of lipogenic
genes was down-regulated and lipolytic gene was up-regulated in BBR-SLNs treated
livers which could be helpful in the treatment of hepatosteatosis [46].
Cisplatin (CSPT) is an anti-cancer drug which is used in the treatment of many
malignancies including hepatocellular carcinoma, lungs carcinoma, etc. The CSPT
loaded SLNs (CSPT-SLNs) were successfully developed and were stable in terms of
drug content after storage for 3 months in different temperature and humid condi-
tions. In vivo tissue distribution study revealed that the developed CSPT-SLNs were
able to deliver a higher amount of CSPT particularly to the liver as compared to the
brain, lungs, and kidney [47].
Sorafenib (SFB), a potent multi-kinase inhibitor possess anti-tumor angiogenesis
effect (block vascular endothelial growth factor (VEGF) and platelet-derived
growth factor receptor (PDGFR)) and is preferentially used in the treatment of
hepatocellular carcinoma. The SFB loaded SLNs (SFB-SLNs) were developed with
an objective of improving bioavailability and reducing adverse effects. The results
of the stability test showed that SRF-SLNs remained stable for more than 1 month at
room temperature. In vivo study of SFB-SLNs revealed improved bioavailability
(increased by 66.7%) with remarkably higher bioaccumulation of drug in the liver
(2.20-fold higher drug selectivity index value) when compared with the SFB
suspension [48].
Primaquine phosphate (PP) is an antimalarial drug that acts on the primary
tissue forms of the Plasmodium which after growth within the liver, initiate the
erythrocytic stage. Thus, PP loaded SLNs (PP-SLNs) were developed with an aim to
deliver liver schizonticide PP directly to the hepatocytes. Stability of the PP-SLNs in
suspension was tested for a period of 3 months in terms of size, poly-dispersity,
ζ-potential, and pH. There were no noteworthy changes in size, poly-dispersity,
ζ-potential, or pH occurred over time. In vivo study report revealed that the
developed SLNs were highly effective (>20%) against hypnozoites/liver stage of
all malarial species with a reduced dose when compared with the conventional
oral dose [49].
5.2 Solid lipid nanoparticles delivering gene
The fibrous scars occurring in the liver due to the increased production and
deposition of hepatic extracellular matrix (ECM) components are called liver fibro-
sis reduce the physiological performance of the liver. Hepatitis viral infection is one
of the major reasons for liver fibrosis and cirrhosis. Administration of antifibrotic
therapeutics (e.g. connective tissue growth factor (siRNA) responsible for the cel-
lular and molecular basis of fibrogenesis) is one of the most preferable approaches
for the treatment of liver fibrosis. The siRNA loaded cationic SLNs (cSLNs) were
developed by gently mixing CSLNs with siRNA at various weight ratios of cSLN to
siRNA in 0.1 M PBS (pH 7.4) and then incubated at room temperature for 15 min.
Naturally obtained low-density lipids (LDLs) were used in the preparation. The
developed cSLN were able to silence the targeted gene in the presence of serum
with notably low cytotoxicity. The cSLNs were PEGylated which were hydrody-
namically stable and were able to protect their siRNA cargo from nuclease degra-
dation during systemic circulation. The developed cSLNs loaded with siRNA
administer through intravenous route delivered siRNA exclusively to the liver and
resulted in a considerable reduction in collagen content and pro-fibrogenic factors
with spectacular progress of pathophysiological symptoms in a liver fibrosis rat
12
Role of Novel Drug Delivery Vehicles in Nanobiomedicine
model. Biodistribution study revealed site-specific delivery and accumulation of
siRNA loaded cSLNs to the liver tissues [50].
5.3 Solid lipid nanoparticles for passive targeting
5.3.1 Polyethylene glycol conjugated (PEGylated) solid lipid nanoparticles for passive
targeting
PEGylated SLNs are reported to be preferentially accumulated in the liver as the
kidney is unable to clear the same. Thus, in liver disorders, liver targeting strategy
using PEGylation technique is used for delivering numerous drugs. Paclitaxel (PTX)
loaded PEGylated SLNs were successfully developed for targeting the liver, in the
case of hepatic carcinoma. The cellular uptake study revealed that PTX loaded
PEGylated SLNs showed prolonged circulation time in plasma and higher
bioaccumulation of drug in the liver when compared with the PTX solution [51].
The preferential drug targeting ability of PEGylated SLNs to cancer cells have
been shown in Figure 2.
5.3.2 Galactosylated lipid [N-hexadecyl lactobionamide] conjugated solid lipid
nanoparticles
The parenchymal cells of the liver contain asialoglycoprotein receptors which
recognize terminal b-D-galactose or N-acetylgalactosamine residues. The N-
hexadecyl lactobionamide (N-HLBA) was synthesized via an amide bond between
the amine group of hexadecylamine and the carboxyl group of lactobionic acid. The
Figure 2.
PEGylated SLN in targeting preferentially to cancer cells.
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lactobionic acid was converted to 1,5-lactone that contain more reactive amine
groups. Cucurbitacin B (CurB), a tetracyclic triterpene shows significant pharma-
cological activities including anti-tumor, anti-hepatitis, hepatocurative and
hepatoprotective. The CurB loaded N-hexadecyl lactobionamide (N-HLBA) conju-
gated SLNs were developed for liver-targeted delivery of CurB. The N-HLBA SLN
with anchored galactose moiety via amide bonds might achieve effective liver-
targeting delivery in vivo by retaining the surface galactose in blood stream, and by
exposing a higher amount of galactose to the liver parenchymal cells. The optimum
zeta potential held up the physical stability whereas the optimum particle size
distribution offered the convenience for intravenous administration and deep pen-
etration into targeting area. The Biodistribution study of the CurB loaded N-
hexadecyl lactobionamide (N-HLBA) conjugated SLNs revealed a 2.5-fold increase
Sl.
no
SLN
(Type)
Lipid
(s)
Preparation
method
Drugs Target Model Comments Ref.
01 SLN SL,
GMS
Emulsification
ultrasonic
dispersion
method
BCL Liver Rats Improved
biodistribution of BCL
in Liver, Superior anti
oxidative and
hydroxyl radical
scavenging abilities
[44]
02 SLN SA Hot-
homogenization
followed by
ultra-sonication
FB Liver HepG2 cell
line, Rats
Anti-oxidant, anti-
inflammatory and
detoxification
potential
[45]
03 SLN GL,
SP, TP
Hot
Emulsification
Technique
BBR Liver Male db/db
mice,
Down regulate the
lipogenic gene and
Up-regulate the
lipolytic gene.
[46]
04 SLN SA Warm
emulsification
followed by
sonication
CSPT Hepatocellular
carcinomas
Wistar rats Higher
bioaccumulation of
drug in liver
[47]
05 SLN GB High-speed
shearing
followed by
ultrasonication
SFB Liver Female SD
Rats
Improved
bioavailability, higher
bioaccumulation in
liver
[48]
06 SLN SA Modified
multiple
emulsion
solvent
evaporation
technique
PP Hepatocytes 3D7, Mice Improved antimalarial
activity
[49]
07 C-SLN CO Modified
emulsification
and solvent
evaporation
method
siRNA LDL Receptor Rat, HSCs
and
hepatocytes
Spectacular progress
of pathophysiological
symptoms in liver
fibrosis
[50]
08 PEG-
SLN
GT,
CHO
Solvent-
emulsification
method
PTX Hepatocytes HepG2,
MCF7,
PANC-1
Higher liver
bioaccumulation of
PTX
[51]
09 G-SLN COMP High-pressure
homogenization
CurB ASGP
Receptor
Wistar rats Enhanced antitumor
and hepatoprotective
activity
[52]
Table 3.
List of SLNs and their different ligand conjugated forms for liver cell targeting.
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in the amount of CurB in the liver when compared with CurB-SLN. In vitro cyto-
toxicity study revealed enhancement of cytotoxicity. The experimental result vali-
dated the liver targeting ability of N-HLBA conjugated SLNs [52].
List of SLNs and their different ligand conjugated form for liver targeting have
been summarized in Table 3.
6. Solid lipid nanoparticles for breast cell targeting
Breast cancer is the most common form of cancer and the second most deadly
disease among the woman around the globe. The breast cancer new incidences and
mortality rate has been increased by 20 and 14% since 2008.
Recently, controlled release of the drugs to the targeted site of the disease using a
nanocarrier vehicle is getting more attention as it enhances the therapeutic efficacy
of the drugs. Solid lipid nanoparticulate (SLN) formulations possess an endless
potential to deliver active chemotherapeutic molecules in a programmed prototype
to improve bioavailability and nullify the side-effects. The bio-compatibility and
bio-degradability characteristics of SLNs promise to offer a lesser toxic product as
compared to polymeric nanoparticles which forced to consider it as an idealistic
targeted drug delivery system for breast cancer therapy [5].
6.1 Solid lipid nanoparticle for active breast cell targeting
6.1.1 SLNs for photodynamic therapy
Photodynamic therapy is one of the emerging approaches in the treatment of
cancer which comprises application of a photosensitizer followed by laser irradia-
tion of tumor lesions. Temoporfin (TP), a photosensitizer loaded in thermore-
sponsive SLNs were developed with an objective to improve anticancer activity
through site specific drug delivery. The copolymer poly(ethylene oxide)-block-
poly(ε-caprolactone) copolymers (PEO45-b-PCL7) were synthesized by the mecha-
nism of catalyst-free ring opening polymerization of ε-caprolactone which was
initiated by poly(ethylene oxide) monomethyl ether(MPEO). These copolymers
were acts as a stabilizer in the preparation of thermoresponsive SLN. The stability
study report revealed that the developed SLNs had higher stability in human serum
within the blood transport to tumor tissue. In vitro phototoxicity study revealed
higher phototoxic activity of TP against breast cancer cells due to its faster
bioaccumulation in the targeted cancer cells. The in vivo anticancer efficacy of TP-
SLN was remarkably higher as compared to the commercial TP formulation [53].
6.1.2 Manganese (Mn) II complex solid lipid nanoparticles
Transition metal complex (e.g., Manganese II complex
[Mn2(μ(C6H5)2CHCOO)2(bipy)4]
 2) has been extensively used for cancer therapy
nowadays due to its potential anticancer activity (interact with the DNA). Mn(II)
complex loaded SLNs were developed that showed superior cytotoxicity activity on
breast cancer cells. The zeta potential value of the product was higher indicating
good physical stability and dispersion quality of the SLNs. Cell proliferation assay
revealed that the normal cell death rate was lower with Mn(II) SLNs which indi-
cated lesser toxicity of the product to the normal cell. Moreover, higher early
apoptosis rate was observed with Mn(II) complex SLN as compared to Mn(II)
alone [54].
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6.2 Solid lipid nanoparticles for passive breast cell targeting
6.2.1 Fucose conjugated solid lipid nanoparticles
Fucose receptors are overexpressed in the breast cancer cell. Thus, conjugation
of fucose to SLNs was proposed to deliver the drug specifically to breast cancerous
cells. Fucose conjugated methotrexate (MTX) loaded SLNs were developed to
achieve enhanced targeting potential for breast cancer cells. Fucosylation of MTX-
SLNs was related with opening of fucose ring and reaction of its aldehyde group
with free amino functionalities expressed over the surface of MTX-SLNs in sodium
acetate buffer (pH 4.0). The above process led to the formation of Schiff’s base (–
N=CH). The Schiff’s base might be reduced to secondary amine (–NHCH2) and
establish equilibrium with Schiff’s base. Physical stability of prepared SLNs was
higher which could be due to positive zeta potential value that provides repulsive
interaction between nanosized lipid particles preventing particle aggregation. The
ex vivo study revealed higher cellular uptake as well as higher cytotoxicity at lower
IC50 of MTX. The in vitro study results showed increased rate apoptosis with a
change in lysosomal membrane permeability and a higher rate of lysosomal
membrane degradation. The in vivo study revealed maximum bioavailability and
tumor targeting efficiency with minimum secondary drug distribution to
other organs [55].
6.2.2 Folic acid functionalized solid lipid nanoparticles
The folate receptor (FR) is one of the most widely evaluated receptor for active
targeting of anticancer therapeutics in the case of in breast cancer cells. Folic acid
has many advantages over antibody ligands such as small size, non-
immunogenicity, non-toxicity, ease of handling, stability and low cost [56]. Several
researchers had reported earlier that the FA functionalized SLNs were able to
deliver the chemotherapeutic agent, particularly to the cancerous cells. Thus, FA
functionalized SLNs co-encapsulated with Docetaxel (DTX) and Curcumin (CUR)
were successfully developed to enhance its therapeutic efficacy against breast can-
cer cells. FA-stearic acid (FA–SA) conjugate was synthesized by classical 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDAC) chemistry and incorporated in the
DTX-CUR-SLN. Additionally, PEG–stearic acid (PEG–SA) was incorporated to
obtain FA-DTX-CUR-SLN. The DTX-CUR-SLN and FA-DTX-CUR-SLN formula-
tions were found to be stable at refrigerated condition for 2 months. Both the
formulations showed sign of instability at accelerated condition (25°C/65% RH).
The developed FA functionalized SLNs exhibited improved pharmacokinetic
parameters, superior cancer cell targeting efficiency, and improved therapeutic
efficacy of DTX. Folic acid was believed to be responsible for the targeting efficacy
of the developed SLNs to the breast cancer cell. This conjugated system showed
significant increase in area under the curve and mean residence time of the drug.
Co-conjugation (FA and PEG) to SLNs co-encapsulated with DTX and CUR
responsible for synergistic activity of both DTX and CUR. Moreover,
bioaccumulation of DTX in heart and kidney was found very low which signified
avoidance of vital organ toxicity [57].
6.2.3 Cetamide and trimethylphytosphingosine-iodide co-conjugated solid lipid
nanoparticles
The sphingosine-1-phosphate (S1P), phytosphingosine, ceramides, and sphin-
gosine are the metabolites of sphingolipids and are reported as essential structural
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components of cell membranes or important mediators of cellular process that
regulate the proliferation, survival, and death of cells. Moreover, sphingosines
including N,N,N-trimethylsphingosine (TMP-I) have been reported for their role as
a negative modulator of transmembrane signaling through protein kinase C (PKC)
as well as an inhibitor of sphingosine kinase-1 (SK-1), controlling the various
membrane-associated signaling mechanisms associated with cell growth and inhib-
itory apoptosis in tumor cells [58]. Ceramide, a kind of sphingosine conjugated with
fatty acid residue, is also reported to enhance the sensitivity of MDR-acquired
cancer cell lines to chemotherapeutic agents [59]. Thus, attempts were made to
employ ceramide (CD) and trimethylphytosphingosine-iodide (TMP-I) as a
targeting agent for docetaxel (DTX) loaded SLNs. The prepared SLNs were physi-
cally stable without any significant change in their physical appearance, drug con-
tent, and particle size over a period of 8 weeks at 4°C. CD enhanced the DTX
sensitivity in MDR-acquired cancer cell lines. In vivo clearance of drug and tumor
growth inhibitors were significantly decreased in case of CD and TMP-I conjugated
SLNs when compared with the marketed product. Thus, CD and TMP-I conjugated
DTX-SLN could serve as a potentials alternative parenteral formulations of
DTX [60].
Sl.
no
SLN
(Type)
Lipid(s) Drugs Preparation
method
Target Model Comments Ref.
01 SLN TD TMP Modified hot
homogenization
and
ultrasonication
method
Breast
Cancer
cell
4T1,
MDA-MB-231,
Female Nu/Nu
mice- MDA-
MB-231
Exhibited
improved
phototoxicity and
anticancer
efficacy
[53]
02 Mn (II)
Complex-
SLN
COMP Mn (II)
complex
Hot
homogenization
method
Breast
Cancer
cell
MCF-7 and
HUVEC cell
line
Possessed
superior
anticancer
activity with
reduced toxic
effect.
[54]
03 F-SLN PL90NG,
PL, STA,
GEL
MTX Hot
microemulsion
method
Fucose
Receptor
MCF-7 Cell
line & Female
SD rat
Improved
bioavailability
and tumor
targeting
efficiency with
minimum
secondary drug
distribution in
various organs.
[55]
04 FA-PEG-
SLN
GMS, SA CUR,
DTX
Modified
ethanol injection
method
Folic
acid
Receptor
MCF-7
&MDA-MB-
231Cell line.
Female Wistar
Rat
Synergistic
cancer efficacy
due to
coencapsulation
of DTX and CRM
along with
targeted
delivery of drugs
[57]
05 CD-TMP
I-SLN
PC, TMS, DTX High-pressure
homogenization
method
CD &
TMP-1
MCF-7 cell,
MCF-7/ADR
cells
Significant
increased
antitumor
efficacy with
targeted drug
delivery
[60]
Table 4.
List of SLNs and their different ligand conjugated forms for breast cancer cell targeting.
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List of SLNs and their different ligand conjugated form for breast cancer cell
targeting have been summarized in Table 4.
7. Solid lipid nanoparticles for eye targeting
The eye is one of the delicate organs of human and one of the most delicate
routes of drug delivery. However, the eye poses unique challenges relative to drug
delivery due to the ocular anatomical and physiological constraints. SLNs are one of
the promising targeted DDS for an eye. Numerous drugs such as antibiotics, plas-
mids, anti-inflammatory, and immunosuppressive agents were encapsulated in
SLNs for the treatment of ophthalmic disorders.
7.1 Solid lipid nanoparticles for active eye targeting
Corneal neovascularization (CNV), a sight-threatening condition is caused due
to various inflammatory settings including chemical injury. Single-stranded
proline-modified short hairpin anti-angiopoietin-like protein 2 (ANGPTL2 RNA)
interference molecules acts as potent angiogenic and pro-inflammatory factor and is
used for the treatment of CNV [61]. Thus, ANGPTL2 RNA loaded SLNs were
developed to deliver the interference molecule specifically to the retina. The single-
stranded RNAi (pshRNA) loaded SLNs exhibit high stability in vivo and preliminary
data suggest that pshRNA is less susceptible to degeneration due to RNase activity.
The fluorescence-labeled developed SLNs eye drops penetrated all layers of cornea
and expression of ANGPTL2mRNA was considerably inhibited in both epithelium
and stroma. Further, the area of angiogenesis was remarkably decreased in the
corneas by the SLNs drops as compared to the control group [62].
X-linked juvenile retinoschisis (XJR), a retinal degenerative disorder caused by
mutation in the RS1 gene encoding a retinoschisin [63]. Among non-viral vectors,
solid lipid nanoparticles (SLNs) represent one of the most effective lipid-based
colloidal carriers, and for gene delivery to the posterior segment of the eye [64].
Plasmid (human RS1 gene) loaded SLNs were developed for the treatment of XJR
diseases which showed significant improvement of the retinal structure with pho-
toreceptor specific expression of the RS1 gene [65].
Tobramycin (TMC) is one of the most preferable drugs to treat vitreoretinal
diseases, such as bacterial infections, endophthalmitis, cytomegalovirus retinitis
(CMV), uveitis, proliferative vitreoretinopathy (PVR), diabetic retinopathy, age-
related macular degeneration [66]. Thus TMC loaded mucoadhesive SLNs were
developed which showed higher bioaccumulation of drugs in most of the ocular tissues
and was able to penetrate into the retina. Moreover, it resulted in enhanced
intraphagocytic antibiotic concentration in polymorphonuclear granulocytes and
superior bactericidal activity against Pseudomonas aeruginosa. The developed SLNs
showed good stability up to 12 months with no aggregation or precipitation phenom-
ena, variations in zeta potential values or in amount of the drug encapsulated into the
nanoparticles [67].
7.2 Solid lipid nanoparticles for passive eye targeting
7.2.1 Chitosan coated solid lipid nanoparticles
Indomethacin (IMC), a topical non-steroidal anti-inflammatory drug (NSAID)
is used for ocular inflammatory disorders such as conjunctivitis, uveitis, cystoid
macular edema, and anterior segment inflammation, including post-operative pain
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following cataract surgery [68]. Chitosan (Cs) coated IMC loaded SLNs (IMC-Cs-
SLN) were developed to deliver NSAID to the posterior segment of ocular tissues
and for improving the pre-corneal residence time and transcorneal permeability
characteristics. For surface modification of the developed SLNs, the chitosan was
incorporated into the aqueous phase prior to preparation of the SLNs. The devel-
oped SLNs were stable in terms of drug loading, EE, and less drug expulsion during
storage at 40°C for 90 days. The SLNs showed higher bioaccumulation of IMC in
the ocular tissues. The IMC-Cs-SLN showed superior trans-membrane IMC
permeation characteristics which were due to penetration enhancing properties
of Cs [69].
7.2.2 Intercalated montmorillonite solid lipid nanoparticles
Betaxolol hydrochloride (BH) is widely used for the treatment of ocular hyper-
tension and open-angle glaucoma in clinical therapeutics. However, it faces certain
limitations like low bioavailability and pre-ocular retention, and some side effects.
Sl.
no
SLN (Type) Lipid(s) Drugs Preparation
method
Target Model Comments Ref.
01 SLN DSGPC,
CHO
ANGPTL2
RNA
Hydration
method
followed by
extrusion
Retina C57BL/6
mice
Inhibition of
expression of
ANGPTL2mRNA,
Reduction in
angiogenesis area
[62]
02 SLN PRE Human RS1
gene
Solvent
emulsification
followed by
evaporation
Retina 661W,
RS1h-
deficient
mouse
Improvement of
the retinal
structure
[65]
03 SLN SA TMC Warm o/w
microemulsion
method
Aqueous
humor
Albino
rabbit
Superior
bactericidal
activity
[67]
04 Cs-SLN GB IMC Hot
homogenization
Posterior
segment of
ocular
tissue
White
albino
Rabbits
Improved
biodistribution of
IMC at posterior
segment
[69]
05 Mt-SLNs PC,
GMS
BH Emulsion
evaporation-
low
temperature
solidification
method
Cornea and
Conjunctiva
Rabbit Significantly
reduced
inflammation, No
irritation
[70]
06 PEG-SLNs COMP KTZ Emulsification
followed by
high pressure
homogenizer
Upper
posterior
eye
ARPE-19
& RCE
Cell line,
Rat
Superior
antifungal activity
[73]
07 Multifunctional
SLNs
CP BAI (Drug)
C IR-780
(Diagnostic
agent)
Modified
solvent-
diffusion
method
Colorectal
part
LoVo,
CHO-K1
Imaging, Superior
cytotoxicity
[75]
08 SIA-PEGylated
SLN
GMS,
OA
DXM Solvent
diffusion
method
E-selectin
receptor
HUVECs,
ICR male
Mice
Targeted delivery
of DXM for
ischemia-
reperfusion-
induced injury-
induced AKI
[78]
Table 5.
List of SLNs and their different ligand conjugated forms for eye, colon and kidney targeting.
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In order to overcome these limitations acid treated montmorillonite (Mt)- Betaxolol
Hydrochloride (BH) nanocomposite encapsulated SLNs (Mt-BH-SLNs) were
developed. An acid-treated montmorillonite (acid-Mt) was first intercalated with
BH in the interlayers and this nanocomposite was encapsulated by SLNs. The
developed Mt-BH-SLNs possess good stability. Long term irritation test reported
that the (Mt-BH-SLNs) showed no damage for cornea and conjunctiva. The corneal
hydration level of Mt-BH-SLNs was higher (78.25  0.63)% indicating higher drug
corneal permeability and absence of irritation to the cornea. Thus, Mt-BH-SLNs
could be used for effective management of glaucoma [70].
7.2.3 Polyethylene glycol (PEG) conjugated (PEGylated) solid lipid nanoparticles
Ketoconazole (KTZ) is a broad spectrum antifungal agent, with high lipo-
solubility [71] but a short ocular half-life (elimination half-life is 19 min in
aqueous humor and 43 min in cornea) [72] and very poor solubility (0.04 mg/ml).
Ketoconazole (KTZ) loaded PEGylated SLNs were developed for targeted delivery
of KTZ to the posterior part of the eye for treatment of fungal infection. It showed
higher bioavailability both in the aqueous and vitreous humor with significant
antifungal potential. The ex vivo corneal permeation study revealed higher corneal
permeability of the PEGylated KTZ-SLNs. The developed SLN was satisfying vari-
ous parameters suitable for ocular delivery such as pH, osmolarity, stability,
autoclavability, particle size, preservation against contamination. The SLNs were
found to be stable in terms of entrapment efficiency and total drug content at 2–8°C
for 12 months. Thus it could be helpful in the treatment of keratitis and
endophthalmitis [73].
List of SLNs and their different ligand conjugated forms for eye targeting have
been summarized in Table 5.
8. Solid lipid nanoparticles for passive colon targeting
Combination of nanocarriers and electroporation techniques is named as
electropermeabilization which is commonly used for enhancing drug transport. The
Cyanine–type IR 780 and Baicalein (BAI) co-encapsulated SLNs were developed for
both imaging and therapy of colorectal carcinoma where cyanine–type IR 780 and
baicalein (flavonoid derivative) were acting as a diagnostic agent (photosensitizer)
and therapeutic cargo respectively. For preparation of SLNs the organic phase was
prepared by dissolving IR-780, BAI, and melted lipid in dichloromethane. The
organic phase was then added dropwise to hot aqueous phase containing surfactant
under vigorous stirring. Supplementary material (flavonoids) facilitated in the
reduction of dose and reduction in normal cell toxicity in cancer chemotherapy. The
external electric field pulses applied in electroporation helped in increased of cell
membrane permeability, either by generating transient pores or membrane
electropermeabilization [74]. Electropermeabilization mediated administration of
the developed SLNs showed cytoskeletal abnormalities more significantly then
without electropermeabilization. The prepared SLNs particles were with good
physical stability. With electroporation support, the developed SLNs showed
increased p53 and manganese superoxide dismutase expression with significant
higher cytotoxicity, thus validating their suitability for combined therapy and
molecular imaging simultaneously [75].
List of SLNs and their different ligand conjugated form for colon targeting have
been summarized in Table 5.
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9. Solid lipid nanoparticles for kidney targeting
9.1 Solid lipid nanoparticles for passive kidney targeting
9.1.1 Polyethylene glycol (PEG) surface modified solid lipid nanoparticles
Icariin (IRN) is widely used as traditional Chinese medicine for the treatment of
kidney diseases and reinforce yang. The PEG surface modified Icariin (IRN) loaded
SLNs (PEG-IRN-SLNs) was developed for targeted delivery of IRN to the kidney
and to improve the bioavailability. The SLN was prepared by high temperature
melt-cool solidification method. Upon comparing with IRN solution it was revealed
from the pharmacokinetic study that the biological half-life (t1/2) and area under
curve (AUC) of PEG-IRN-SLN was 7-fold and 4-fold higher. Biodistribution study
revealed that IRN concentration in kidney tissues was significantly increased.
Moreover, the relative target efficiency to kidney tissues was 79% and relative tissue
exposure was 16.95. Thus the develop SLN could be helpful in the treatment of
kidney diseases [76].
9.1.2 Sialic acid conjugated PEGylated solid lipid nanoparticles
E-selectin is a promising target for the site-specific delivery of anti-
inflammatory agents. Several researchers have reported that sialic acid (SA)-medi-
ated micelles could be specifically internalized by lipopolysaccharide (LPS)-acti-
vated human umbilical vein endothelial cells (HUVECs) via the specific binding
between SA and E-selectin receptor [77]. Sialic acid (SIA) conjugated PEGylated
dexamethasone (DXM) loaded SLNs (SIA-PEGylated-DXM-SLN) were developed
to deliver DXM specifically to the kidney and to improve the therapeutic efficacy of
DXM for renal ischemia–reperfusion injury (IRI)-induced acute renal injury. The
Sialic acid (SIA) conjugated PEGylated DXM (SIA-PEG-DXM) was synthesized by
adding PEG-DXM, dicyclohexylcarbodiimide (DCC), and 4-dimethylamino-
pyridine (DMAP) into anhydrous dimethyl formamide (DMF) followed by addition
of SIA into the solution. The resulting mixture was stirred for obtaining SIA-PEG-
DXM. The crude product was purified by dialysis against deionized water for
2 days, followed by lyophilization. The developed SLNs potentially had good colloi-
dal stability in human body. The study revealed that the apoptotic human umbilical
vein endothelial cells (HUVECs) were significantly decreased. It indicated the suit-
ability of SIA-PEGylated-SLNs for internalization by the inflamed vascular endo-
thelial cells. Biodistribution study revealed higher renal accumulation of DXM
(range 2.7- to 5.88-fold higher) after 6 h of intravenous administration. The Phar-
macodynamic study revealed that higher blood biochemical indexes, histopatho-
logical changes, oxidative stress levels, and pro-inflammatory cytokines which
indicated improved renal function by the influence of SIA-PEGylated DXM [64].
List of SLNs and their different ligand conjugated form targeting to the kidney
have been summarized in Table 5.
10. Conclusion
Though drug targeting to a specific site in the body is an interesting approach, it is
a highly challenging task. Despite that a large variety of smart nanocarriers have been
developed for drug targeting in recent years, SLN has achieved a special status among
them and can be employed for both passive as well as active targeting. These can be
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employed for delivering not only the drug but also antibody, proteins, genes, imaging
agents etc. and bring about increased cellular uptake at the targeted disease sites.
Moreover, surface modification of SLNs through conjugation of various ligands on
SLNs surfaces helped in enhancing its targeting efficacy in terms of cellular binding,
uptake and intracellular transport to different cells as well as organs and ensure its
greatest potentiality to combat wide ranges of diseases. However, the intrinsic com-
plexity of biological environments strongly influences its functionality and often
complicates their effective use for therapeutic treatments. Therefore, a deeper
knowledge and understanding of the real interactions involved in the diseased tissues
is fundamental for the development of therapeutic protocols of SLNs.
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Abbreviations
AM alveolar macrophages
ANGPTL2 RNA single-stranded proline-modified short hairpin anti-
angiopoietin-like protein 2
AP-E apolipoprotein E
ASGP asialoglycoprotein
BAI baicalein
BBR berberine
BCL baicalin
BH betaxolol hydrochloride
CHO cholesterol
CIR-780 cyanine-type IR-780
CMP camptothecin
CO cholesterol oleate
COMP compritol 888 ATO
CP cetyl palmitate
CRM carmustine
c-SLN cationic SLN
CSPT cisplatin
Cs-SLN chitosan coated SLNs
CUR curcumin
CurB curcumin B
DM dimyristoyl
DMPC 1,2-dimyristoyl-sn-glycero-3-phospho-choline
DSPE Distearoylphosphatidyl-ethanolamine
DSPEG 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[carboxy
(polyethylene glycol)-2000]
DSGPC 1,2-distearoyl-sn-glycero-3-phosphocholine
DTX docetaxel
DXM dexamethasone
FA-PEG-SLN folic acid-polyethylene glycol cross conjugated SLN
FB Ficus benjamina
FR folate receptor
F-SLN fucose conjugated SLN
Ft-SLN folate conjugated SLN
GB glyceryl behenate
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GEL Gelucire®50/13
GL glycerol
GMS glyceryl monostearate
GS glyceryl stearate
G-SLNs galactosylated lipid conjugated SLNs
GT glycerol trioleate
GTP glyceryl tripalmitate
GTS Glycerol tristearate
HSC hepatic stellate cells
IMC indomethacin
LDL low density lipid
LfR lactoferrin receptor
Lf-SLN lactoferrin SLN
KTZ ketoconazole
MIC minimum inhibitory concentration
Mn (II) complex [Mn2(l (C6H5)2CHCOO)2(bipy)4](bipy)(ClO4)2 complex
MR mannose receptor
Msy-SLN mannosylated SLN
Mt. intercalated montmorillonite SLN
MTX methotrexate
PA palmitic acid
PC phosphatidylcholine
PEG-SLN PEGylated SLNs
PL phospholipid
PL90NG Phospholipon 90NG
PP primaquine phosphate
PRE Precirol ATO5
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
PTX paclitaxel
RIF rifampicin
RFB rifabutin
RSV resveratrol
RLZ riluzole
SA stearic acid
SFB sorafenib
SL soya lecithin
SIA sialic acid
siRNA small interfering RNA
SD Sprague-Dawley
SP soybean phospholipid
SPC soya phosphatidylcholine
STA stearyl amine
TD 1-tetradecanol
TMC tobramycin
TMP temoporfin
TMP-I trimethylphytosphingosine-iodide
TMS trimyristin
TP tripalmitate
TSN tristearin
VIN vinpocetine
WGA-SLN wheat germ agglutinin conjugated SLN
3D7 asexual intraerythrocytic stage of P. falciparum laboratory
strain (3D7)
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